FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4386572703> ?p ?o ?g. }

• W4386572703 abstract "Exploratory analyses of high-dose alkylating chemotherapy trials have suggested that BRCA1 or BRCA2-pathway altered (BRCA-altered) breast cancer might be particularly sensitive to this type of treatment. In this study, patients with BRCA-altered tumors who had received three initial courses of dose-dense doxorubicin and cyclophosphamide (ddAC), were randomized between a fourth ddAC course followed by high-dose carboplatin-thiotepa-cyclophosphamide or conventional chemotherapy (initially ddAC only or ddAC-capecitabine/decetaxel [CD] depending on MRI response, after amendment ddAC-carboplatin/paclitaxel [CP] for everyone). The primary endpoint was the neoadjuvant response index (NRI). Secondary endpoints included recurrence-free survival (RFS) and overall survival (OS). In total, 122 patients were randomized. No difference in NRI-score distribution (p = 0.41) was found. A statistically non-significant RFS difference was found (HR 0.54; 95% CI 0.23-1.25; p = 0.15). Exploratory RFS analyses showed benefit in stage III (n = 35; HR 0.16; 95% CI 0.03-0.75), but not stage II (n = 86; HR 1.00; 95% CI 0.30-3.30) patients. For stage III, 4-year RFS was 46% (95% CI 24-87%), 71% (95% CI 48-100%) and 88% (95% CI 74-100%), for ddAC/ddAC-CD, ddAC-CP and high-dose chemotherapy, respectively. No significant differences were found between high-dose and conventional chemotherapy in stage II-III, triple-negative, BRCA-altered breast cancer patients. Further research is needed to establish if there are patients with stage III, triple negative BRCA-altered breast cancer for whom outcomes can be improved with high-dose alkylating chemotherapy or whether the current standard neoadjuvant therapy including carboplatin and an immune checkpoint inhibitor is sufficient. Trial Registration: NCT01057069." @default.
• W4386572703 created "2023-09-10" @default.
• W4386572703 creator A5000718039 @default.
• W4386572703 creator A5002039163 @default.
• W4386572703 creator A5003016287 @default.
• W4386572703 creator A5010512189 @default.
• W4386572703 creator A5011172949 @default.
• W4386572703 creator A5019767096 @default.
• W4386572703 creator A5020517461 @default.
• W4386572703 creator A5021689879 @default.
• W4386572703 creator A5021960841 @default.
• W4386572703 creator A5026661285 @default.
• W4386572703 creator A5026959007 @default.
• W4386572703 creator A5030542961 @default.
• W4386572703 creator A5033195086 @default.
• W4386572703 creator A5039966148 @default.
• W4386572703 creator A5041673964 @default.
• W4386572703 creator A5043405731 @default.
• W4386572703 creator A5043575344 @default.
• W4386572703 creator A5048535376 @default.
• W4386572703 creator A5058336805 @default.
• W4386572703 creator A5062462121 @default.
• W4386572703 creator A5062791488 @default.
• W4386572703 creator A5063335991 @default.
• W4386572703 creator A5063757732 @default.
• W4386572703 creator A5063917865 @default.
• W4386572703 creator A5064453966 @default.
• W4386572703 creator A5070619938 @default.
• W4386572703 creator A5076006564 @default.
• W4386572703 creator A5078080248 @default.
• W4386572703 creator A5079501701 @default.
• W4386572703 creator A5084438796 @default.
• W4386572703 creator A5087130965 @default.
• W4386572703 date "2023-09-09" @default.
• W4386572703 modified "2023-10-16" @default.
• W4386572703 title "High-dose alkylating chemotherapy in BRCA-altered triple-negative breast cancer: the randomized phase III NeoTN trial" @default.
• W4386572703 cites W1562387252 @default.
• W4386572703 cites W1919187471 @default.
• W4386572703 cites W1973560717 @default.
• W4386572703 cites W1976927712 @default.
• W4386572703 cites W1991573648 @default.
• W4386572703 cites W2000366267 @default.
• W4386572703 cites W2056609529 @default.
• W4386572703 cites W2086064725 @default.
• W4386572703 cites W2096745115 @default.
• W4386572703 cites W2109868732 @default.
• W4386572703 cites W2113734556 @default.
• W4386572703 cites W2125062016 @default.
• W4386572703 cites W2133258471 @default.
• W4386572703 cites W2135750130 @default.
• W4386572703 cites W2143596381 @default.
• W4386572703 cites W2146165949 @default.
• W4386572703 cites W2152061559 @default.
• W4386572703 cites W2169790254 @default.
• W4386572703 cites W2170719826 @default.
• W4386572703 cites W2174514097 @default.
• W4386572703 cites W2288454796 @default.
• W4386572703 cites W2535064044 @default.
• W4386572703 cites W2596164112 @default.
• W4386572703 cites W2788106879 @default.
• W4386572703 cites W2888205332 @default.
• W4386572703 cites W2889646458 @default.
• W4386572703 cites W2898861270 @default.
• W4386572703 cites W2909799373 @default.
• W4386572703 cites W2944687997 @default.
• W4386572703 cites W2979547848 @default.
• W4386572703 cites W3003213753 @default.
• W4386572703 cites W3162334759 @default.
• W4386572703 cites W3165576985 @default.
• W4386572703 cites W4225673975 @default.
• W4386572703 cites W4229079181 @default.
• W4386572703 doi "https://doi.org/10.1038/s41523-023-00580-9" @default.
• W4386572703 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37689749" @default.
• W4386572703 hasPublicationYear "2023" @default.
• W4386572703 type Work @default.
• W4386572703 citedByCount "0" @default.
• W4386572703 crossrefType "journal-article" @default.
• W4386572703 hasAuthorship W4386572703A5000718039 @default.
• W4386572703 hasAuthorship W4386572703A5002039163 @default.
• W4386572703 hasAuthorship W4386572703A5003016287 @default.
• W4386572703 hasAuthorship W4386572703A5010512189 @default.
• W4386572703 hasAuthorship W4386572703A5011172949 @default.
• W4386572703 hasAuthorship W4386572703A5019767096 @default.
• W4386572703 hasAuthorship W4386572703A5020517461 @default.
• W4386572703 hasAuthorship W4386572703A5021689879 @default.
• W4386572703 hasAuthorship W4386572703A5021960841 @default.
• W4386572703 hasAuthorship W4386572703A5026661285 @default.
• W4386572703 hasAuthorship W4386572703A5026959007 @default.
• W4386572703 hasAuthorship W4386572703A5030542961 @default.
• W4386572703 hasAuthorship W4386572703A5033195086 @default.
• W4386572703 hasAuthorship W4386572703A5039966148 @default.
• W4386572703 hasAuthorship W4386572703A5041673964 @default.
• W4386572703 hasAuthorship W4386572703A5043405731 @default.
• W4386572703 hasAuthorship W4386572703A5043575344 @default.
• W4386572703 hasAuthorship W4386572703A5048535376 @default.
• W4386572703 hasAuthorship W4386572703A5058336805 @default.
• W4386572703 hasAuthorship W4386572703A5062462121 @default.
• W4386572703 hasAuthorship W4386572703A5062791488 @default.
• W4386572703 hasAuthorship W4386572703A5063335991 @default.
• W4386572703 hasAuthorship W4386572703A5063757732 @default.

• next